NOVATO, Calif., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced that its Chief Executive Officer, Christopher M. Starr, Ph.D., will present an overview of the Company at three investor conferences in February.
The conference presentation schedule is as follows:
| Leerink Swann 2012 Global Healthcare Conference |
| February 16, 2012 at 3:30pm ET |
| The Waldorf Astoria, New York, NY |
| Citi 2012 Global Healthcare Conference |
| February 27, 2012 at 2:00pm ET |
| The Waldorf Astoria, New York, NY |
| 2012 RBC Capital Markets' Global Healthcare Conference |
| February 28, 2012 at 4:35pm ET |
| The Palace Hotel, New York, NY |
A live audio webcast and 14-day archive of the Citi and RBC presentations will be available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180